TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15892532
Drug: Sealants without
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealants without a bonding agent
Study: 12510039
Drug: Two infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two infusions of 6 mg of natalizumab per kilogram
Study: 12510039
Drug: Two infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two infusions of 3 mg of natalizumab per kilogram
Study: 12510039
Drug: Groups receiving
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups receiving two infusions of natalizumab
Study: 8834062
Drug: Low-intensity anticoagulation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity anticoagulation (e.g., warfarin)
Study: 1829981
Drug: Metoprolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (1 x 100 mg/day)
Study: 1829981
Drug: Cilazapril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (1 x 2.5 mg/day)
Study: 6410908
Drug: methylprednisolone 80
Normalized name: methylPREDNISolone 80 mg/mL injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone 80 mg intravenously plus Vivonex‐HN, 2 L/day po
Study: 6410908
Drug: methylprednisolone 80
Normalized name: methylPREDNISolone 80 mg/mL injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone 80 mg intravenously plus total parenteral nutrition, 2.5 L/day
Study: 6410908
Drug: total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: total parenteral nutrition, 2.5 L/day
Study: 6410908
Drug: Vivonex‐HN, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vivonex‐HN, 2 L/day po
Study: 30910388
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control (maintenance of sinus rhythm by catheter ablation and/or antiarrhythmic drugs)
Study: 29527702
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tadalafil once a day for 6 weeks
Study: 29527702
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral multivitamin tablet) once a day for 6 weeks
Study: 27630326
Drug: 2 vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 vs. 5 years of treatment with zoledronic acid
Study: 20054553
Drug: Epirubicin 20
Normalized name: epiRUBicin 200 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 20 mg/40 ml saline
Study: 20054553
Drug: Epirubicin 50
Normalized name: epiRUBicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 50 mg/100 ml
Study: 16708818
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Jianweiyuyang granules and ranitidine capsules
Study: 16708818
Drug: Ranitidine capsules
Normalized name: Ranitidine Capsules
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine capsules
Study: 12843349
Drug: BFV value
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFV value of 220 mL/min
Study: 10228253
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with intravenous midazolam
Study: 10228253
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with intravenous saline (placebo group)
Study: 10228253
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous cannula (control group)
Study: 9305489
Drug: Cisapride 60
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride 60 mg (2 x 30 mg suppositories)
Study: 9302150
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg twice daily
Study: 2391738
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg twice daily
Study: 29621048
Drug: Tongue pressure
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue pressure strength and accuracy training (TPSAT) with traditional dysphagia therapy for 30 minutes each per day, 5 times per week for 8 weeks
Study: 29621048
Drug: Traditional dysphagia
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dysphagia therapy for 30 minutes twice a day, 5 times per week for 8 weeks
Study: 28237859
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus monthly lifestyle group education sessions of 45min duration
Study: 26174128
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol 400 μg
Study: 21631568
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg/day (CX2)
Study: 13677263
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy followed by stem-cell rescue
Study: 8471513
Drug: Psoralen-UVB treatment
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoralen-UVB treatment
Study: 9092744
Drug: Conventional psoralen-UVA
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional psoralen-UVA treatment
Study: 8458681
Drug: SQ29,852 (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ29,852 (mean dose 15.0 ± 5.1 mg/day)
Study: 8458681
Drug: Atenolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (mean dose 37.5 ± 18.5 mg/day)
Study: 31785056
Drug: Prostaglandin (PG)
Normalized name: PG
DrugBank: 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DB11331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin (PG) inpatient group (Dinoprostone, either 2 mg gel or 10 mg controlled-release tape)
Study: 27230616
Drug: Custom-made serially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custom-made serially adjustable rigid wrist/hand orthoses (WHO), prescribed for 6 hours nightly (or daily) for 3 years.
Study: 24387929
Drug: Bladder neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder neck sling suspension technique
Study: 20402874
Drug: suxamethonium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 1.5 mg.kg(‐1) (Group S)
Study: 20402874
Drug: rocuronium 1
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 1 mg.kg(‐1) (Group R)
Study: 20402874
Drug: suxamethonium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 1.5 mg.kg(‐1) (Group SO)
Study: 15668474
Drug: Oophorectomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oophorectomy and tamoxifen treatment for breast cancer
Study: 30187221
Drug: Immunonutrition supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrition supplements
Study: 30187221
Drug: Standard polymeric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard polymeric supplements
Study: 30187221
Drug: Nutrition supplements
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition supplements (both types)
Study: 30256102
Drug: Single water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single water treatment interventions
Study: 30256102
Drug: Single water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single water treatment and handwashing interventions
Study: 30256102
Drug: Water treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water treatment and handwashing
Study: 24192062
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of leukotriene receptor antagonist (LRA), H1 antihistamine, and H2 antihistamine (Group A)
Study: 24192062
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continued with previously taken two combination regimens (Group B)
Study: 17618330
Drug: Systemic metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic metronidazole and amoxicillin (500 mg amoxicillin + 250 mg metronidazole every eight hours for seven days) with scaling and root planing
Study: 17618330
Drug: Systemic metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic metronidazole and amoxicillin with scaling and root planing
Study: 15274152
Drug: Combined fibrinolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined fibrinolysis with 50 mg of alteplase and abciximab (n = 34)
Study: 15274152
Drug: Primary angioplasty
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary angioplasty with adjunctive abciximab (n = 36)
Study: 9704725
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg mitomycin bound to a solution of 375 mg carbo adsorbens intraperitoneally before closure of the abdominal wound (n = 46)
Study: 9704725
Drug: M-CH therapy
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-CH therapy
Study: 8208399
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum concentration of 4-aminopyridine (30 to 59 ng/ml)
Study: 8208399
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum concentration of 4-aminopyridine (60 to 100 ng/ml)
Study: 2536599
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF) administered at 15 ng/kg/min for hour 1 and 50 ng/kg/min for hour 2, preceded by a 50-micrograms bolus
Study: 25491276
Drug: Intra-articular platelet-rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular platelet-rich plasma (PRP) injection
Study: 24317850
Drug: Antitumor treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitumor treatment
Study: 19469186
Drug: New therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapeutic approaches targeting TRPV1 receptors, cytokine receptors, neuropeptide receptors, glutamate receptors, sodium and calcium channels.
Study: 10510990
Drug: Cilostazol, 100
Normalized name: Cilostazol, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol, 100 mg, twice a day
Study: 10510990
Drug: Cilostazol, 50
Normalized name: Cilostazol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol, 50 mg, twice a day
Study: 7862386
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium (100 U/mL)
Study: 27896921
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (27 mg of iron)
Study: 26498958
Drug: Arthroscopic acromioplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic acromioplasty (AA) with autologous PRP injection (AA + PRP)
Study: 23485610
Drug: Extended-release carbidopa-levodopa
Normalized name: carbidopa / levodopa Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release carbidopa-levodopa
Study: 17317877
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline intravenous
Study: 17317877
Drug: 0.45% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% saline intravenous
Study: 17317877
Drug: 0.45% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% saline oral
Study: 15548244
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine sulfate (SRMS) 30 mg
Study: 11496941
Drug: Transdermal oxybutynin
Normalized name: oxybutynin Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oxybutynin (OXY) administered via a single transdermal system over a 96 h wear period
Study: 11496941
Drug: Oral oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxybutynin (OXY) administered as a single 5 mg immediate-release tablet
Study: 8172137
Drug: 1 MU
Normalized name: benzocaine/cetalkonium 5-1 MUCOUS MEM TROCHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 MU of L-IFN
Study: 8172137
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU of L-IFN
Study: 8172137
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU of L-IFN (24 weeks after stopping treatment)
Study: 8172137
Drug: 1 MU
Normalized name: benzocaine/cetalkonium 5-1 MUCOUS MEM TROCHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 MU of L-IFN (24 weeks after stopping treatment)
Study: 8172137
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (24 weeks after stopping treatment)
Study: 8172137
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (2',5'-Oligoadenylate synthetase activities)
Study: 8172137
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU of L-IFN (anti-HCV titers)
Study: 30454042
Drug: Continuous landiolol
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous landiolol infusion to reach a target HR of 80-94 bpm along with standard treatment according to the Surviving Sepsis Campaign Guidelines 2016
Study: 28027332
Drug: 25 mg/d
Normalized name: fluoride 0.25 mg/drop oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/d opicapone
Study: 28027332
Drug: 50 mg/d
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d opicapone
Study: 26122504
Drug: MON-400BUD (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MON-400BUD (low-dose inhaled budesonide + montelukast)
Study: 26122504
Drug: 800BUD (medium-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800BUD (medium-dose inhaled budesonide)
Study: 23316693
Drug: Hyperinsulinaemic hyperglycaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinaemic hyperglycaemic clamp (50 m-units·m⁻²·min⁻¹, 10 mmol/l)
Study: 23316693
Drug: Hyperglycaemic euinsulinaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemic euinsulinaemic clamp (10 mmol/l, 5 m-units·m⁻²·min⁻¹)
Study: 23316693
Drug: Hyperinsulinaemic euglycaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinaemic euglycaemic clamp (50 m-units·m⁻²·min⁻¹, 4.5 mmol/l)
Study: 28506003
Drug: Bilateral EMG-triggered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral EMG-triggered multi-channel electrostimulation + mirror therapy
Study: 23506170
Drug: Insecticide-treated nets
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insecticide-treated nets (ITNs) distributed to treatment group households
Study: 24505200
Drug: Bimatoprost/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost/timolol fixed combination (BTFC)
Study: 15279042
Drug: First generation
Normalized name: First generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: First generation antipsychotic medications
Study: 8843207
Drug: Nevirapine at
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine at doses > or = 240 mg/m2/day
Study: 1292918
Drug: L-carnitine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (4 g/day for 12 months)
Study: 6828970
Drug: 2 gram
Normalized name: fructose 2 gram ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 gram intravenous bolus dose of cefamandole
Study: 29259310
Drug: rhIL-2 injection
Normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-2 injection
Study: 20190918
Drug: Treatment withdrawal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment withdrawal for all participants
Study: 17721095
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg daily escalated to 40 mg daily for 16 weeks)
Study: 11241253
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (3.75 g calcium carbonate daily)
Study: 2543895
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (Estraderm)
Study: 10029561
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments pooled
Study: 29877724
Drug: Therapy as
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy as Usual (TAU)
Study: 28591133
Drug: bioavailable RC
Approvals — FDA: no, EMA: no, PMDA: no
Description: bioavailable RC extract (RCE), providing 34 mg/d isoflavones and probiotics
Study: 28591133
Drug: masked placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: masked placebo formulation
Study: 23661240
Drug: PTHrP(1-36) 400
Normalized name: 1-36 hpthrp
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTHrP(1-36) 400 µg/day
Study: 23661240
Drug: PTHrP(1-36) 600
Normalized name: 1-36 hpthrp
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTHrP(1-36) 600 µg/day
Study: 23661240
Drug: PTH(1-34) 20
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH(1-34) 20 µg/day
Study: 9431774
Drug: NobleBiocare HC200
Approvals — FDA: no, EMA: no, PMDA: no
Description: NobleBiocare HC200 bone‐anchored hearing aid (BAHA) implant
Study: 1559296
Drug: Levothyroxine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (mean dose 2.82 +/- 0.6 micrograms/kg/day)
Study: 31715140
Drug: Multiuser virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiuser virtual reality (MU) therapy
Study: 31715140
Drug: Single-user virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-user virtual reality (SU) therapy
Study: 31715140
Drug: Both MU
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both MU and SU therapy
Study: 28277921
Drug: Dexamethasone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (3 IM doses of 8 mg, 8 hours apart)
Study: 27806033
Drug: Arthrem® (ART)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrem® (ART) 150 mg twice-daily
Study: 24500080
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control condition)
Study: 21358208
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (35 mg/m2, days 1, 8, and 15; q4w)
Study: 21358208
Drug: Standard docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard docetaxel (75 mg/m2 every 3 weeks; q3w)
Study: 21358208
Drug: Weekly arm
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly arm (q1w)
Study: 18782780
Drug: enfuvirtide discontinuation
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: enfuvirtide discontinuation arm
Study: 10673875
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg kg‐1 i.v. (group TM)
Study: 31233409
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with dexmedetomidine (0.3 μg/kg)
Study: 25190522
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg intranasal nicotine
Study: 12925475
Drug: Acetaminophen 40
Normalized name: acetaminophen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 40 mg/kg
Study: 11758634
Drug: Acetaminophen 100
Normalized name: acetaminophen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 100 mg/kg
Study: 2492011
Drug: Beta- and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta- and gamma-interferon combination therapy
Study: 19880586
Drug: Walnut-enriched ad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-enriched ad libitum diet (56 g walnuts/day)
Study: 17984413
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (l-glutamine, 0.3 g/kg per day)
Study: 16167232
Drug: Titanoreine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanoreine cream (n=133)
Study: 16167232
Drug: Compound carraghenates
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound carraghenates suppository (n=119)
Study: 9469683
Drug: 6-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-hour infusion of furosemide (0.1 mg/kg loading dose, followed by 0.9 mg/kg over 6 hours)
Study: 9469683
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of furosemide (1 mg/kg over 2 minutes, followed by a 6-hour placebo infusion)
Study: 7631260
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with carboplatin, ifosfamide, and etoposide followed by carboplatin and vindesine, and hyperfractionated accelerated radiotherapy (1.5 Gy 10 times per week for a total of 45 Gy in 3 weeks)
Study: 18030070
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg tid)
Study: 720378
Drug: Noradrenaline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline plus propranolol 10 microgram/ml
Study: 720378
Drug: Noradrenaline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline plus propranolol 10 microgram/ml plus oxprenolol 3 microgram/ml
Study: 720378
Drug: Noradrenaline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline plus propranolol 13 microgram/ml